RECRUITINGOBSERVATIONAL

The Application of T1 Mapping in Real-World

The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort

About This Trial

The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are: What are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler "native T1" measurement (without contrast dye) instead of the more complex "ECV" measurement (which requires contrast dye) for diagnosis? Patients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping

Who May Be Eligible (Plain English)

Who May Qualify: 1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines. 2. Specific disease categories include: - Cardiomyopathies (HCM, DCM, RCM, ACM) - Infiltrative disorders (cardiac amyloidosis, Fabry disease) - Inflammatory conditions (acute/chronic myocarditis) - Ischemic heart disease (acute/chronic MI) - Valvular heart disease (aortic stenosis) - Arrhythmic conditions (atrial fibrillation) - Metabolic disorders (iron-overload) - Neoplastic conditions (cardiac tumors) - Congenital heart disease - Post-transplant evaluation 3. All diagnoses must be confirmed using established guideline-based criteria: - Echocardiographic parameters meeting disease-specific cutoffs - Cardiac MRI findings consistent with current consensus criteria - Laboratory biomarkers supporting respective diagnoses - Histopathological confirmation when clinically indicated Who Should NOT Join This Trial: - Presence of multiple cardiomyopathy diseases or risk factors simultaneously - Contraindications to CMR examination - Poor image quality precluding accurate T1 mapping analysis - Incomplete clinical data for definitive diagnosis confirmation - Pregnancy or lactation - Inability to provide willing to sign a consent form Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines. 2. Specific disease categories include: * Cardiomyopathies (HCM, DCM, RCM, ACM) * Infiltrative disorders (cardiac amyloidosis, Fabry disease) * Inflammatory conditions (acute/chronic myocarditis) * Ischemic heart disease (acute/chronic MI) * Valvular heart disease (aortic stenosis) * Arrhythmic conditions (atrial fibrillation) * Metabolic disorders (iron-overload) * Neoplastic conditions (cardiac tumors) * Congenital heart disease * Post-transplant evaluation 3. All diagnoses must be confirmed using established guideline-based criteria: * Echocardiographic parameters meeting disease-specific cutoffs * Cardiac MRI findings consistent with current consensus criteria * Laboratory biomarkers supporting respective diagnoses * Histopathological confirmation when clinically indicated Exclusion Criteria: * Presence of multiple cardiomyopathy diseases or risk factors simultaneously * Contraindications to CMR examination * Poor image quality precluding accurate T1 mapping analysis * Incomplete clinical data for definitive diagnosis confirmation * Pregnancy or lactation * Inability to provide informed consent

Treatments Being Tested

DIAGNOSTIC_TEST

Magnetic Resonance Imaging with Contrast

Participants in this arm undergo a single, standardized cardiac MRI scan with gadolinium-based contrast agent.

Locations (1)

Fuwai Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China